1 The mechanisms underlying the vasodilator response to urocortin are incompletely understood. The present study was designed to examine the role of endothelial nitric oxide and Ba The endothelium of the coronary artery was moderately stained with the antiserum against urocortin. 6 Taken together, the present results indicate that the urocortin-induced endothelium-dependent relaxation of rat coronary arteries is likely attributable to endothelial nitric oxide and subsequent activation of Ba 2+ -or tertiapin-Q-sensitive K + channels. The urocortin-induced endotheliumdependent relaxation appears to be mediated by cyclic GMP-dependent mechanisms.
Introduction
Corticotropin-releasing factor (CRF), a 41-amino acid peptide produced mainly in the hypothalamus, is believed to be the principal neuromediator of the hypothalamicpituitary-adrenal stress axis in mammals (Vale et al., 1981) . Several structurally related peptides of the CRF family include ®sh neuropeptide urotensin (Pearson et al., 1980) , sauvagine (Erspamer et al., 1980) , and urocortin (Vaughan et al., 1995) . The action of CRF-related peptides are mediated through binding to two G protein-coupled receptors derived from two distinct genes (Potter et al., 1994; Lovenberg et al., 1995b) . There exists at least three alternatively spliced forms of Type-2 CRF receptor, CRF-R2a, CRF-R2b and CRF-R2g (Lovenberg et al., 1995b; Kishimoto et al., 1995) .
Although these receptors are widely distributed throughout the mammalian brain, CRF-R2 is the only type of CRF receptor detected in the heart (Kishimoto et al., 1995; Lovenberg et al., 1995a; Perrin et al., 1995) . Two subtypes of CRF-R2 are expressed in cardiac tissues, CRF-R2a in human (Chen et al., 1993) and CRF-R2b in rats (Stenzel et al., 1995) . Urocortin II selectively binds to type 2 CRF receptors (Reyes et al., 2001) . Urocortin II shares a signi®cant sequence homology to CRF and the coincident expression of CRF-R2 receptors with urocortin ligands in the heart suggests that urocortin may play a physiological role in the cardiac activity. Urocortin or CRF exerted positive ionotropic eect, elevated cardiac output and caused coronary vasodilatation in sheep and rats (Parkes et al., 1997; Terui et al., 2001) . This eect may be associated with increased production of cardiac cyclic AMP level resulting from stimulation of adenylyl cyclase (Heldwein et al., 1996) . The cardiac eect can be achieved by urocortin within a narrow nanomolar concentration range. Urocortin mRNA was expressed by both cultured neonatal rat cardiomyocytes and the adult rat heart; urocortin transcripts were increased after simulated hypoxia/ischemia (Brar et al., 1999) . Urocortin exerted cardioprotective eect against cell death following ischemic and reperfusion injury via a MAPKdependent signaling pathway (Brar et al., 2000) . Besides, urocortin stimulated secretion of atrial natriuretic peptide and brain natriuretic peptide from neonatal rat cardiomyocytes (Ikeda et al., 1998) . Both urocortin mRNA and CRF-R2b mRNA are expressed in the cultured rat cardiac myocytes. Urocortin mRNA expression was upregulated in left ventricular hypertrophy (Nishikimi et al., 2000) . Urocortin immunoreactivity was found to be more intense in cardiomyocytes from human failing hearts than from normal hearts (Nishikimi et al., 2000) . These new ®ndings indicate that urocortin may play a role in the pathophysiology of cardiac hypertrophy or heart failure.
Urocortin and CRF-related peptides are extremely potent vasodilators. Systemic administration of CRF-related peptides lowered blood pressure in human (KuÈ bler et al., 1994) and in experimental animals (Lenz et al., 1985; Lei et al., 1993; Richter & Mulvany, 1995; Vaughan et al., 1995) . In vitro studies show that these peptides produced potent vasorelaxation in human foetal vessels (Clifton et al., 1994; Leitch et al., 1998) and in rat cerebral artery (Schilling et al., 1998) .
Urocortin and CRF-related peptides were found to decrease coronary perfusion pressure in isolated rat heart via coronary vasodilatation (Terui et al., 2001) . The coronary vasodilating and the positive ionotropic eects of urocortin may underpin its potential cardiac protective action. However, the exact mechanisms underlying the urocortin-induced coronary vasodilatation remain unclear. The present study aimed at investigating the role of endothelium and K + channels in the coronary vasorelaxant response to urocortin by measuring isometric tone of ring segments of the isolated rat left anterior descending coronary artery on small vessel myograph.
Methods

Artery preparation and mounting
The experimental protocols were approved by the Animal Research Ethics Committee of the Chinese University of Hong Kong. Male Sprague-Dawley rats (*300 ± 330 g) were killed by cervical dislocation. The heart was rapidly removed and placed in a dissecting plate containing ice-cold Krebs solution. The left anterior descending arteries were carefully dissected out. After the surrounding tissues were cleaned o, each artery was cut into 2 ± 3 cylindrical segments *1.5 mm in length.
Ring segments were mounted in a Multi Myograph System (Danish Myo Technology A/S, Denmark) and changes in vessel tension were recorded. Brie¯y, two tungsten wires (each of 40 mm diameter) were passed through the segment's lumen and each wire ®xed to jaws of myograph. The chamber bath was ®lled with 5 ml Krebs solution. The Krebs solution contained (mM): NaCl 119, KCl 4.7, CaCl 2 2.5, MgCl 2 1, NaHCO 3 25, KH 2 PO 4 1.2 and D-glucose 11. Each ring was bathed in Krebs solution that was continually aerated with a gas mixture of 95% O 2 plus 5% CO 2 . The Krebs solution in the chamber was maintained at 378C using a built-in heat-exchange device. The pH values were between 7.3 and 7.5. The segment was stretched between the wires under a previously determined optimal tension of 0.5 mN. Two ring-segments were prepared from each rat. The rings were allowed to stabilize at a baseline tone for 90 min before the start of the experiments. Each experiment was carried out on rings prepared from dierent rats. In total, 84 rats were used in this study.
Experimental design
After equilibration in Krebs solution for 30 min, each vessel was initially contracted by 3610
78 M U46619 to test its contractile capacity followed by addition of 3610 76 M acetylcholine to test integrity of the endothelium. The ring was then rinsed three times with an interval of 20 min and baseline tone was readjusted when necessary.
In the ®rst set of experiments, 3610 78 M U46619 was used to generate sustained vessel tone; the relaxant responses to cumulative concentration of urocortin were subsequently studied. To determine the role of the endothelium, the responses to urocortin were examined in endotheliumdenuded rings. The urocortin-induced relaxation was also examined in endothelium-intact rings pretreated with 10 74 M L-NAME, 10 75 M methylene blue or 10 75 M ODQ (30-min incubation time) to assess the involvement of nitric oxide or cyclic GMP-dependent pathway. To examine whether the substrate of nitric oxide synthase, L-arginine, would counteract with the eect of L-NAME, some endothelium-intact rings were incubated with 5610 74 M L-arginine for 10 min before the addition of 10 74 M L-NAME.
In the second group of experiments, the endothelium-intact rings were incubated for 30 min with K 72 M) as compared with the rings constricted by U46619. To study the role of prostacyclin, rings were exposed to 10 75 M indomethacin for 30 min prior to addition of U46619. In order to localize the site of action for BaCl 2 , BaCl 2 was examined on the relaxation induced by hydroxylamine or nitroprusside in the endothelium-denuded rings. The rings were pretreated for 30 min with various inhibitors (BaCl 2 , tertiapin-Q, L-NAME, ODQ, methylene blue) before addition of U46619. Once a steady tone was established, the nitric oxide donor was applied cumulatively.
Since pretreatment with inhibitors of nitric oxide-cyclic GMP pathway or of K + channels, could increase the U46619-induced tone, the concentration of U46619 was lowered between 2610 78 and 3610 78 M in order to produce a similar amplitude of vessel tension in dierent rings.
In some rings, the endothelium was mechanically removed by rubbing the luminal surface of the ring several times with small stainless steel wire (40 mm in diameter). The functional denuation of the endothelium was con®rmed if the relaxant response to 3610 76 M acetylcholine was lacking in the beginning of each experiment. In experiments using high K + -containing solution, an equimolar concentration of K + replaced Na + in order to retain a constant ionic strength.
Immunohistochemistry
The anaesthetized male Sprague-Dawley rats of approximately 300 g in weight were perfused with freshly prepared 4% paraformaldehyde in 0.1 M phosphate buered saline (PBS) via the left ventricle. The left anterior descending coronary arteries were dissected from the hearts with the coronary arteries en bloc were further ®xed overnight in the same ®xative and embedded in paran. Paran sections of cross-sections of coronary arteries were cut. Hydrated sections were treated with 0.3 ± 0.5% H 2 O 2 in absolute methanol for 30 min, followed by washing in PBS and incubated in a blocking solution containing 0.1% bovine serum albumin (BSA) and 0.3 ± 0.5% Tween-20 in PBS for 15 min. Sections were then incubated with a rabbit antiserum against synthetic rat urocortin (Y360 or Y361, Peptide Institute, Inc., Osaka, Japan), diluted 1 : 200 in the blocking solution, overnight at room temperature in a moist chamber. Control sections were incubated with the blocking solution without primary antiserum. After washing in PBS, sections were incubated with a biotin-labelled goat anti-rabbit IgG (Jackson ImmunResearch Laboratories, Inc., West Grove, PA, U.S.A.) for 1 h at room temperature, followed by 1 h with avidin-biotin-peroxidase complex. The immunoreactive sites were then visualized by a glucose oxidase-diaminobenzidine (DAB)-nickel method (Chan & Choi, 1995) and appeared as dark blue or black in colour.
Chemicals
Phenylephrine hydrochloride, acetylcholine chloride, urocortin (human), indomethacin, N G -nitro-L-arginine methyl ester (L-NAME), L-arginine, charybdotoxin (CTX), apamin, 9,11-dideoxy-11a,9a-epoxy-methanoprostaglandin F 2a (U46619), methylene blue, barium chloride, tetraethylammonium ions, hydroxylamine, sodium nitroprusside (Sigma, St. Louis, MO,
tertiapin-Q (Tocris, U.K.). Antiserum against rat urocortin was purchased from Peptide Institute, Inc. (Osaka, Japan). Indomethacin U46619 and ODQ were dissolved in dimethyl sulphoxide. 0.2% DMSO did not aect U46619-induced tension. Stock solution of urocortin was prepared in 0.1 N HCl and desired dilution was made daily before experiments. Other chemicals were dissolved in distilled water.
Data analysis
Several rings prepared from the same artery were studied in parallel, and a concentration-response curve was established in each ring. The relaxant eect of urocortin was quanti®ed as the percentage reduction of the initial tone in each ring preconstricted by U46619. Concentration-relaxation curves were constructed based on the responses to cumulative concentrations of urocortin and analysed by non-linear curve ®tting using Graphpad software (Version 3.0). The negative logarithm of the relaxant concentration that caused 50% of the maximum relaxation (pD 2 ) and the maximum relaxation (E max ) were calculated. For statistical analysis, Student's ttest or one-way analysis of variance followed by NewmanKeuls test was used when more than two treatments were compared. Statistically signi®cance was accepted when P50.05. The results are mean+s.e.mean and n represents a number of rings prepared from dierent rats.
Results
The relaxant effect of urocortin
Traces in Figure 1a show that cumulative application of urocortin induced concentration-dependent relaxation in endothelium-intact rings preconstricted with U46619. Urocortin produced signi®cantly less relaxation in the endothelium-denuded rings without an eect on the maximum relaxation ( Figure 1b) . Figure 1c shows the concentrationresponse curves for urocortin-induced relaxant response in endothelium-intact and denuded rings with pD 2 8.64+0.03 (n=15) and 7.90+0.10 (n=8), respectively (P50.05, Figure  6 ). In the endothelium-intact rings preconstricted with 3.5610 72 M K + , urocortin at the same concentration range induced only partial relaxation with 31.9+5.5% maximal relaxation (n=4) and urocortin failed to relax 5610 Figure 1d ).
Nitric oxide inhibitors
In the endothelium-intact rings pretreated with 10 74 M L-NAME, urocortin-induced relaxant response was signi®cantly attenuated (n=7, Figure 2a ). The pD 2 value was 8.09+0.09 (n=7), close to that obtained in endothelium-denuded rings ( Figure 6 ). Pretreatment with nitric oxide precursor, Larginine (5610 74 M) did not in¯uence urocortin-induced relaxation (n=4, Figures 2b and 6 ), but it prevented the inhibitory eect of 10 74 M L-NAME on urocortin-induced relaxation in endothelium-intact rings (n=5, Figure 2b ). Methylene blue at 10 75 M or ODQ at 10 75 M inhibited urocortin-induced relaxation with similar potency (n=5, Figures 2c and 6 ).
K
+ channel inhibitors Figure 3a shows that in endothelium-intact rings preconstricted by U46619, urocortin-induced concentrationdependent relaxation was signi®cantly attenuated by pretreatment with 10 74 M BaCl 2 or 10 76 M tertiapin-Q (pD 2 : 8.11+0.07, n=6 in BaCl 2 and 8.06+0.10, n=6 in tertiapin-Q, P50.05 compared with control, Figure 3b) . Furthermore, co-treatment with 10 74 M BaCl 2 plus 10 74 M L-NAME did not produce additive inhibition of urocortin-induced relaxation (pD 2 : 8.00+0.10, n=6, Figure 3a ) as compared with BaCl 2 or L-NAME alone (P40.05, Figure 6 ). Besides, following the relaxant response to urocortin (2610
BaCl 2 (10 76 ± 10 74 M) concentration-dependently reversed the urocortin-induced relaxation in endothelium-intact rings (n=5, Figure 3c ). In the endothelium-denuded rings, pretreatment with 10 74 M BaCl 2 had no eect on urocortininduced relaxation (pD 2 : 7.79+0.24, n=6, P40.05 compared with control, Figures 3d and 6) . BaCl 2 at 10 74 M did not aect baseline tone in both endothelium-intact and -denuded rings (data not shown).
The concentration-dependent response to urocortin was inhibited by 10 73 M TEA + (pD 2 : 8.21+0.12, n=6, P50.05 compared with control, Figures 4a and 6 ), but was unaected by a combination of 10 77 M CTX and 10 77 M apamin (pD 2 : 8.69+0.03, n=6, P40.05 compared with control, Figures 4b  and 6 ).
Indomethacin or ouabain
In endothelium-intact rings preconstricted by U46619, neither indomethacin (10 75 M) nor ouabain (10 74 M) aected the relaxation of U46619-contracted endothelium-intact rings induced by urocortin (pD 2 : 8.55+0.05, n=4 in indomethacin and 8.63+0.05, n=5 in ouabain, P50.05 compared with control, Figures 5 and 6 ).
Nitric oxide donors-induced relaxation
In the endothelium-denuded rings preconstricted by 2610 78 M U46619, hydroxylamine induced concentrationdependent relaxation with pD 2 of 6.48+0.06 (n=8, Figure  7c) . Trace in Figure 7a shows the control relaxant response to hydroxylamine. Pretreatment with BaCl 2 (10 74 M) signi®- 75 M ODQ. All experiments were conducted in endotheliumintact rings. Each ring was exposed to L-NAME, methylene blue or ODQ for 30 min prior to application of U46619. Results are mean+s.e.mean of n experiments. *Signi®cantly dierent from control; P50.05.
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Urocortin and coronary relaxation Y. Huang et al cantly attenuated the hydroxylamine-induced relaxation without aecting the maximal response (pD 2 : 6.06+0.07, n=8 in BaCl 2 , P50.05 compared with control, Figure 7b,d) . But tertiapin-Q (10 76 M) had no eect (pD 2 : 6.36+0.04, n=8, Figure 7d) , and 7.95+0.06 in tertiapin-Q, n=6 in each case). Methylene blue (10 75 M, n=5) but not L-NAME (10 74 M, n=5) signi®cantly reduced the relaxant response to hydroxylamine (Figure 7c ). ODQ at 10 75 M abolished the relaxation induced by hydroxylamine (n=4, Figure 7c ) or by nitroprusside (n=6).
Immunochemistry
The endothelium of the coronary artery moderately reacted with the antiserum against urocortin (Figure 8b,c) . The smooth muscle cell layer was not stained. No positive staining was seen when the primary antiserum was replaced by the blocking solution (Figure 8c ).
Discussion
This study characterizes some mechanisms by which urocortin acts as a potent dilator of the rat left anterior descending coronary arteries. The major and new ®ndings of this study include: (1) urocortin induces both endotheliumdependent and -independent coronary relaxation and endothelial nitric oxide is the primary mediator of the endothelium-dependent response; (2) urocortin-induced endothelium-dependent relaxation is likely mediated via a cyclic GMP-related mechanism; and (3) urocortin-induced endothelium-dependent relaxation is inhibited by BaCl 2 and Figure 6 pD 2 values were calculated as the negative logarithm of the urocortin concentration inducing 50% maximum relaxation after various pharmacological treatments in isolated rat coronary artery rings. Results are mean+s.e.mean of n experiments. *Indicates a signi®cant dierence from the control (with endothelium). 
Role of the endothelium
A recent study has shown that CRF and urocortin decreased coronary perfusion pressure (CPP) at a constant¯ow rate in the isolated rat heart, indicating that both peptides possess a coronary vasodilator eect (Terui et al., 2001 ). Our results demonstrate a very potent vasorelaxant eect of urocortin with an IC 50 of 2.24 nM in the isolated rat coronary arteries with intact endothelium. A signi®cant decrease in the potency of urocortin is observed in the endothelium-denuded rings (IC 50 of 12.5 nM) even though the maximum relaxation to urocortin remains unchanged. However, it was previously shown that a small vasodilator eect of urocortin (4% reduction of CPP) started to occur only at 86 nM and a moderate decrease in CPP (27%) was obtained with urocortin at 206 nM (Terui et al., 2001) . This value (206 nM) is approximately 16 fold the IC 50 value calculated for urocortin-induced coronary relaxation in the isolated endothelium-denuded rings. It is likely that other factors may aect the coronary response to urocortin in the intact heart. For example, urocortin was also found to exert positive ionotropic action that may complicate its vasodilator eect. It is not known whether regional dierences in the response to urocortin exist in coronary circulation, which could partly explain the discrepancy in the relaxing potency of urocortin between the isolated rings and the whole vasculature. However, the endothelium was found to play little role in urocortininduced relaxation in the isolated rat mesenteric artery (Lei et al., 1993) and rat basilar artery (Schilling et al., 1998) . In contrast, CRF-induced relaxation was markedly blunted by endothelium removal in rat uterine artery (Jain et al., 1999) and rat aorta (Jain et al., 1997) . These data indicate that the endothelium may have dierential role in dierent vessels that are chosen for testing the vascular eect of urocortin.
Inhibitors of nitric oxide-dependent vasodilation
Removal of the endothelium attenuates the relaxant eect of urocortin, indicating that the endothelial-derived factors are involved. It is well known that various physiological stimuli including endogenous neuropeptides which trigger Ca 2+ in¯ux in the endothelial cells, regulate the contractility of vascular smooth muscle by liberating a number of vasoactive agents, both relaxing and constricting from the endothelium. The balance between the two opposing forces determines the net eect of these factors on vasomotor activity. Nitric oxide, prostacyclin and hyperpolarizing factor are the three major types of vasodilators produced in the endothelium, which act via a variety of cellular mechanisms. Pretreatment with L-NAME, an inhibitor of nitric oxide synthase, or with methylene blue and ODQ, inhibitors of guanylyl cyclase, inhibited the urocortin-induced relaxation to the same degree as observed in the endothelium-denuded rings. In contrast, indomethacin, an inhibitor of prostacyclin formation, had not eect. These results point to a primary role of nitric oxide/cyclic GMP-dependent pathway but not the relaxing prostanoids in the endothelium-dependent relaxant response to urocortin. Similarly, N G -nitro-L-arginine, another inhibitor of nitric oxide synthase, reduced the vasodilator eect of CRF in the isolated rat heart (Grunt et al., 1993) and in human foetal-placental vessels (Clifton et al., 1995) .
Our results, however, do not support a recent report that in the isolated rat heart L-NAME did not aect urocortininduced decrease in CPP (Terui et al., 2001) . This dierence However, no reaction is seen in the smooth muscle cell layer (6200). The calibration bar indicates 100 mm in (a) and (b) and 50 mm in (c).
British Journal of Pharmacology vol 135 (6) Urocortin and coronary relaxation Y. Huang et almay be partly due to the dierent concentrations of urocortin used in the two studies. Our study shows that urocortin caused endothelial nitric oxide-mediated relaxation at concentrations between 1 and 30 nM. Urocortin at 30 nM or higher induces only the endothelium-independent response. On the other hand, in the study using the isolated heart, the concentrations used to dilate the intact coronary vasculature were between 86 and 660 nM. If all vessels in the heart respond to urocortin in a similar manner as that in the isolated left anterior descending coronary artery, it is reasonable to suggest that the endothelial nitric oxidedependent component of the relaxation may have been masked by higher concentrations of urocortin.
Inhibitors of K + channels
The other novel ®nding of the present investigation is that activation of the K + channels is likely involved in the urocortin-induced endothelium-dependent coronary vasorelaxation. Firstly, urocortin-induced relaxation was markedly reduced and almost abolished in rings preconstricted with 35 and 50 mM K + , respectively. One major consequence of raising extracellular K + concentration is to narrow the electrochemical driving force for K + eux, so that the eect of K + channel activation is minimized. Secondly, the urocortin-mediated relaxant eect was signi®cantly inhibited by BaCl 2 or tertiapin-Q, at concentrations used to selectively block the activity of K IR channels in coronary arterial smooth muscle cells (Robertson et al., 1996; Xu et al., 1999) or in cardiac myocyte (Jin et al., 1999; Kitamura et al., 2000) . In the urocortin-relaxed rings, BaCl 2 induces concentrationdependent (1 ± 100 mM) contraction. In contrast, BaCl 2 did not aect urocortin-induced relaxation in endotheliumdenuded rings, indicating a BaCl 2 -sensitive element in urocortin-induced relaxation in endothelium-intact vessels but not in endothelium-denuded vessels. This contention is supported by our observation that combined treatment with L-NAME and BaCl 2 did not produce additive eect. It appears that urocortin stimulates release of endothelial nitric oxide which then acts on the plasma membrane Ba 2+ -sensitive K + channels of the underlying arterial smooth muscle cells. In isolated rabbit middle cerebral arteries, BaCl 2 (10 ± 300 mM) or inhibition of nitric oxide synthase reduced ow-induced relaxation only in the endothelium-intact preparations; BaCl 2 had no eect following endothelium removal or nitric oxide synthase inhibition (Wellman & Bevan, 1995) .
The present study indicates that BaCl 2 probably acts on arterial smooth muscle cells instead of the endothelium. This is suggested by the observation that BaCl 2 at the same concentration also inhibits the relaxant response of endothelium-denuded rings to hydroxylamine or nitroprusside, the nitric oxide donors (Huang, 1998) . A similar observation was also made in endothelium-denuded canine cerebral arteries in which BaCl 2 (300 mM) signi®cantly reduced relaxation induced by the exogenous nitric oxide donors, 3-morpholinosydnonimine and nitroprusside (Onoue & Katusic, 1997) .
It is interesting to note that BaCl 2 but not tertiapin-Q inhibited hydroxylamine-or nitroprusside-induced relaxation, while both blocking agents reduced the urocortin-mediated relaxation to the same extent. It is at present unknown what had caused this discrepancy. It can not be ruled out that the mode of action of these two blockers against the nitric oxidemediated response may be dierent between naturally occurring nitric oxide from the endothelium and nitric oxide released from its exogenous donors.
Urocortin-induced relaxation was unaected by glibenclamide at a concentration that selectively inhibited arterial K ATP channels (Standen et al., 1989) , indicating that K ATP channels are not involved. Similarly, glibenclamide did not aect the relaxation induced by CRF-related peptides in rat uterine artery (Jain et al., 1999) or cerebral artery (Schilling et al., 1998) .
Direct activation of K Ca channels by nitric oxide was reported in vascular smooth muscle cells (Mistry & Garland, 1998) . In non-vascular smooth muscle cells, urocortin produces hyperpolarization via stimulation of K Ca currents (Petkova-Kirova et al., 2000) . Although urocortin-induced relaxation is partially inhibited by tetraethylammonium ions, a non-selective blocker of K + channels, our data do not indicate that urocortin could activate K Ca channels since urocortin-induced relaxation was unaected by inhibition of both large-and small-conductance K Ca channels. Besides, BaCl 2 has little eect on arterial K Ca channels (Nelson & Quayle, 1995) .
In resistance-sized rat vessels, acetylcholine-induced opening of endothelial K Ca channels allows eux of K + ions that diuse between endothelium and vascular smooth muscle layers. Local K + buildup (acting as an endothelium-derived hyperpolarizing factor) then activates two ion transporting proteins, K IR channel and Na + -K + -ATPase in vascular smooth muscle (Edwards et al., 1998) . Increased extracellular [K + ] is also found to activate K IR currents in coronary myocytes and this eect is sensitive to inhibition by BaCl 2 (Xu et al., 1999) . However, it is unlikely that urocortin activates endothelial K Ca channels since its eect is not in¯uenced by a combined treatment with charybdotoxin plus apamin, a recipe used to block K + eux through endothelial K Ca channels (Edwards et al., 1998) . Lack of eect of ouabain suggests that Na 
Summary
The present study is the ®rst attempt to examine the mechanisms by which urocortin relaxes rat coronary arteries. Taken together, the results of this investigation suggest that both endothelial nitric oxide and subsequent activation of BaCl 2 -sensitive K + channel in arterial smooth muscle cells mediates the endothelium-dependent component of urocortininduced coronary relaxation. Cyclic GMP-dependent mechanism seems to be involved. We also detected immunoreactivity of urocortin in the endothelial layer of the rat coronary arteries. This suggests that urocortin may be locally produced in blood vessels. If this occurs in the endothelial cells, urocortin may function as a new member of endothelium-derived vasoactive agents.
